Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) has received a Notice of Allowance from the USPTO for a composition-of-matter patent covering tablet forms of benzgalantamine (ZUNVEYL), their treatment for mild to moderate Alzheimer's disease. This patent, once issued, will provide protection for ZUNVEYL's current formulation in the United States through 2044.
The Notice of Allowance signifies that the USPTO has determined the claimed invention is patentable and a patent should be granted. This milestone strengthens Alpha Cognition's ability to extend patent life beyond 2042 to 2044 in the U.S. market. The company plans to pursue similar patent approvals globally.
CEO Michael McFadden stated that this allowance provides an important layer of proprietary intellectual property protection for ZUNVEYL, their FDA-approved medication for mild to moderate Alzheimer's disease.
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ha ricevuto una Notifica di Concessione dal USPTO per un brevetto sulla composizione della materia che copre le forme in compresse di benzgalantamina (ZUNVEYL), il loro trattamento per l'Alzheimer da lieve a moderato. Questo brevetto, una volta emesso, garantirà protezione per la formulazione attuale di ZUNVEYL negli Stati Uniti fino al 2044.
La Notifica di Concessione indica che l'USPTO ha stabilito che l'invenzione rivendicata è brevettabile e che un brevetto dovrebbe essere concesso. Questo traguardo rafforza la capacità di Alpha Cognition di estendere la durata del brevetto oltre il 2042 fino al 2044 nel mercato statunitense. L'azienda prevede di perseguire approvazioni di brevetti simili a livello globale.
Il CEO Michael McFadden ha dichiarato che questa concessione fornisce uno strato importante di protezione della proprietà intellettuale esclusiva per ZUNVEYL, il loro farmaco approvato dalla FDA per l'Alzheimer da lieve a moderato.
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) ha recibido un Aviso de Concesión de la USPTO para un patente de composición de materia que cubre las formas de tabletas de benzgalantamina (ZUNVEYL), su tratamiento para el Alzheimer leve a moderado. Esta patente, una vez emitida, proporcionará protección para la formulación actual de ZUNVEYL en los Estados Unidos hasta 2044.
El Aviso de Concesión significa que la USPTO ha determinado que la invención reclamada es patentable y se debe conceder un patente. Este hito fortalece la capacidad de Alpha Cognition para extender la vida del patente más allá de 2042 hasta 2044 en el mercado estadounidense. La compañía planea buscar aprobaciones de patente similares a nivel global.
El CEO Michael McFadden declaró que esta concesión proporciona una capa importante de protección de propiedad intelectual exclusiva para ZUNVEYL, su medicamento aprobado por la FDA para el Alzheimer leve a moderado.
알파 코그니션 주식회사 (CSE: ACOG) (OTCQB: ACOGF)는 USPTO로부터 물질 조성 특허 안내를 받아, 알츠하이머 질환의 경증에서 중등증 치료제인 벤즈갈란타민(ZUNVEYL)의 정제 형태에 대한 허가를 받았습니다. 이 특허는 발급되면 ZUNVEYL의 현재 제형에 대해 미국에서 2044년까지 보호를 제공합니다.
안내 공지는 USPTO가 청구된 발명이 특허가 가능하다고 판단했음을 나타내며, 특허가 부여되어야 함을 의미합니다. 이 이정표는 알파 코그니션이 미국 시장에서 2042년에서 2044년으로 특허 기간을 연장할 수 있는 능력을 강화합니다. 이 회사는 글로벌 차원에서 유사한 특허 승인도 추진할 계획입니다.
CEO 마이클 맥패든은 이 허가가 ZUNVEYL에 대한 중요한 독점 지식 재산 보호 층을 제공한다고 언급했습니다. 이는 그들의 FDA 승인 약물로서의 경증 및 중등도 알츠하이머 질환 치료제입니다.
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) a reçu un Avis de Concession de l'USPTO pour un brevet sur la composition de matière couvrant les formes de comprimés de benzgalantamine (ZUNVEYL), leur traitement pour la maladie d'Alzheimer légère à modérée. Ce brevet, une fois délivré, offrira une protection pour la formulation actuelle de ZUNVEYL aux États-Unis jusqu'en 2044.
L'Avis de Concession indique que l'USPTO a déterminé que l'invention revendiquée est brevetable et qu'un brevet doit être accordé. Ce jalon renforce la capacité d'Alpha Cognition à étendre la durée du brevet au-delà de 2042 jusqu'en 2044 sur le marché américain. L'entreprise prévoit de poursuivre des approbations de brevet similaires à l'échelle mondiale.
Le PDG Michael McFadden a déclaré que cette concession fournit une couche importante de protection de la propriété intellectuelle exclusive pour ZUNVEYL, leur médicament approuvé par la FDA pour la maladie d'Alzheimer légère à modérée.
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) hat vom USPTO eine Mitteilung über die Genehmigung für ein Materiekompositionspatent erhalten, das die Tablettenformen von Benzgalantamin (ZUNVEYL), ihrer Behandlung für leicht bis mittelschwere Alzheimer-Erkrankungen, abdeckt. Dieses Patent, sobald es erteilt wird, bietet Schutz für die aktuelle Formulierung von ZUNVEYL in den Vereinigten Staaten bis 2044.
Die Mitteilung über die Genehmigung bedeutet, dass das USPTO festgestellt hat, dass die beanspruchte Erfindung patentierbar ist und ein Patent erteilt werden sollte. Dieser Meilenstein stärkt die Fähigkeit von Alpha Cognition, die Patentenutzerrechte über das Jahr 2042 hinaus bis 2044 im US-Markt auszudehnen. Das Unternehmen plant, ähnliche Patentgenehmigungen weltweit anzustreben.
CEO Michael McFadden erklärte, dass diese Genehmigung eine wichtige Schicht des exklusiven geistigen Eigentumsschutzes für ZUNVEYL, ihr von der FDA zugelassenes Medikament für leicht bis mittelschwere Alzheimer-Erkrankungen, bietet.
- Received Notice of Allowance for composition-of-matter patent for ZUNVEYL
- Patent protection extended through 2044 in the United States
- Strengthens proprietary intellectual property protection for lead asset
- None.
This Notice of Allowance is a critical milestone in our mission to develop transformative therapies for Alzheimer’s disease. It not only recognizes the innovative nature of our research but also strengthens the Company’s ability to extend patent life beyond 2042 to 2044 in
"Allowance of this composition-of-matter patent application, covering a tablet form of benzgalantamine, provides another important layer of proprietary intellectual property protection for our lead asset, ZUNVEYL, an FDA-approved medication for the treatment of mild to moderate Alzheimer’s disease," said Michael McFadden, Chief Executive Officer of Alpha Cognition.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a pre-commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI, which latter candidate is expected to be out-licensed to Alpha Seven Therapeutics Inc. (“Alpha Seven”) a newly incorporated related entity.
This news release includes forward-looking statements within the meaning of applicable
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015620783/en/
For further information:
Michael McFadden, CEO
Tel: 1-858-344-4375
info@alphacognition.com
Source: Alpha Cognition Inc.
FAQ
What patent did Alpha Cognition (ACOGF) receive a Notice of Allowance for?
How long will the new patent protect ZUNVEYL (ACOGF) in the United States?
What is ZUNVEYL by Alpha Cognition (ACOGF) used to treat?